<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39384892</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>10</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>12</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>09</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Biochemical rationale for transfusion of high titre COVID-19 convalescent plasma.</ArticleTitle><Pagination><StartPage>23579</StartPage><MedlinePgn>23579</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">23579</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-024-75093-x</ELocationID><Abstract><AbstractText>We aimed to model binding of donor antibodies to virus that infects COVID-19 patients following transfusion of convalescent plasma (CCP). An immunosorbent assay was developed to determine apparent affinity (K<sub>d, app</sub>). Antibody binding to virus was modelled using antibody concentration and estimations of viral load. Assay and model were validated using reference antibodies and clinical data of monoclonal antibody therapy. A single K<sub>d, app</sub> or two resolvable K<sub>d, app</sub> were found for IgG in 11% or 89% of CCP donations, respectively. For IgA this was 50%-50%. Median IgG K<sub>d, app</sub> was 0.8nM and 3.6nM for IgA, ranging from 0.1-14.7nM and 0.2-156.0nM respectively. The median concentration of IgG was 44.0nM (range 8.4-269.0nM) and significantly higher than IgA at 2.0nM (range 0.4-11.4nM). The model suggested that a double CCP transfusion (i.e. 500 mL) allows for &gt; 80% binding of antibody to virus provided K<sub>d, app</sub> was &lt; 1nM and concentration &gt; 150nM. In our cohort from the pre-vaccination era, 4% of donations fulfilled these criteria. Low and mid-range viral loads are found early post exposure, suggesting that convalescent plasma will be most effective then. This study provides a biochemical rationale for selecting high affinity and high antibody concentration CCP transfused early in the disease course.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Verbrugghe</LastName><ForeName>Caro</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Transfusion Research Center, Belgian Red Cross-Flanders, Ghent, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wouters</LastName><ForeName>Elise</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Transfusion Research Center, Belgian Red Cross-Flanders, Ghent, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Devloo</LastName><ForeName>Rosalie</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Transfusion Research Center, Belgian Red Cross-Flanders, Ghent, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nurmi</LastName><ForeName>Visa</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Nuffield Department of Medicine, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Virology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seghers</LastName><ForeName>Sabrina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Transfusion Innovation Center, Belgian Red Cross-Flanders, Ghent, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Bleser</LastName><ForeName>Dominique</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Transfusion Innovation Center, Belgian Red Cross-Flanders, Ghent, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harvala</LastName><ForeName>Heli</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Radcliffe Department of Medicine, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Microbiology Services, NHS Blood and Transplant, Colindale, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Infection and Immunity, University College of London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Compernolle</LastName><ForeName>Veerle</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Transfusion Research Center, Belgian Red Cross-Flanders, Ghent, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Transfusion Innovation Center, Belgian Red Cross-Flanders, Ghent, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Blood Services of the Belgian Red Cross-Flanders, Mechelen, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feys</LastName><ForeName>Hendrik B</ForeName><Initials>HB</Initials><AffiliationInfo><Affiliation>Transfusion Research Center, Belgian Red Cross-Flanders, Ghent, Belgium. hendrik.feys@rodekruis.be.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium. hendrik.feys@rodekruis.be.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>, Ottergemsesteenweg 413, Ghent, 9000, Belgium. hendrik.feys@rodekruis.be.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007070">Immunoglobulin A</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007116" MajorTopicYN="Y">Immunization, Passive</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093522" MajorTopicYN="Y">COVID-19 Serotherapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="Y">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="Y">Immunoglobulin G</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007070" MajorTopicYN="N">Immunoglobulin A</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019562" MajorTopicYN="N">Viral Load</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001782" MajorTopicYN="N">Blood Donors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Affinity</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Convalescent plasma</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Transfusion</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>10</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>10</Day><Hour>0</Hour><Minute>38</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>9</Day><Hour>23</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39384892</ArticleId><ArticleId IdType="pmc">PMC11464705</ArticleId><ArticleId IdType="doi">10.1038/s41598-024-75093-x</ArticleId><ArticleId IdType="pii">10.1038/s41598-024-75093-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rojas, M. et al. Convalescent plasma in Covid-19: possible mechanisms of action. Autoimmun. rev.19, 102554. 10.1016/j.autrev.2020.102554 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7198427</ArticleId><ArticleId IdType="pubmed">32380316</ArticleId></ArticleIdList></Reference><Reference><Citation>Iannizzi, C. et al. Convalescent plasma for people with COVID-19: a living systematic review. Cochrane Database Syst. Reviews. 10.1002/14651858.CD013600.pub6 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10171886</ArticleId><ArticleId IdType="pubmed">37162745</ArticleId></ArticleIdList></Reference><Reference><Citation>Senefeld, J. W. et al. Mortality rates among hospitalized patients with COVID-19 treated with Convalescent plasma: a systematic review and Meta-analysis. Mayo Clin. Proceedings: Innovations Qual. Outcomes. 7, 499–513. 10.1016/j.mayocpiqo.2023.09.001 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10582279</ArticleId><ArticleId IdType="pubmed">37859995</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine, A. C. et al. Coronavirus Disease 2019 Convalescent plasma outpatient therapy to prevent outpatient hospitalization: a Meta-analysis of individual Participant Data from 5 randomized trials. Clin. Infect. Dis.76, 2077–2086. 10.1093/cid/ciad088 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10273382</ArticleId><ArticleId IdType="pubmed">36809473</ArticleId></ArticleIdList></Reference><Reference><Citation>Körper, S. et al. Results of the CAPSID randomized trial for high-dose convalescent plasma in severe COVID-19 patients. J. Clin. Investig.131, e152264. 10.1172/JCI152264 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8516466</ArticleId><ArticleId IdType="pubmed">34464358</ArticleId></ArticleIdList></Reference><Reference><Citation>Joyner, M. J. et al. Convalescent plasma antibody levels and the risk of death from Covid-19. N Engl. J. Med.384, 1015–1027. 10.1056/NEJMoa2031893 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7821984</ArticleId><ArticleId IdType="pubmed">33523609</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartelt, L. A. et al. Outcomes of Convalescent Plasma with defined high versus lower neutralizing antibody titers against SARS-CoV-2 among hospitalized patients: CoronaVirus Inactivating plasma (CoVIP) study. mBio. 13, e0175122. 10.1128/mbio.01751-22 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9601237</ArticleId><ArticleId IdType="pubmed">36135380</ArticleId></ArticleIdList></Reference><Reference><Citation>Belov, A. et al. Early administration of COVID-19 convalescent plasma with high titer antibody content by live viral neutralization assay is associated with modest clinical efficacy. Am. J. Hematol.97, 770–779. 10.1002/ajh.26531 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9082011</ArticleId><ArticleId IdType="pubmed">35303377</ArticleId></ArticleIdList></Reference><Reference><Citation>Libster, R. et al. Early high-titer plasma therapy to prevent severe Covid-19 in older adults. N Engl. J. Med.384, 610–618. 10.1056/NEJMoa2033700 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7793608</ArticleId><ArticleId IdType="pubmed">33406353</ArticleId></ArticleIdList></Reference><Reference><Citation>Letter of Authorization, Reissuance of Convalescent Plasma EUA February 4. (2021). https://www.fda.gov/media/141477/downloadUS Department of Health and Human Services Food and Drug Administration, (2021).</Citation></Reference><Reference><Citation>Steenhuis, M. et al. Quality assessment and harmonization of laboratories across Europe for multiple SARS-CoV-2 serology assays. Vox Sang. 118, 666–673. 10.1111/vox.13480 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37401414</ArticleId></ArticleIdList></Reference><Reference><Citation>Harvala, H. et al. Convalescent plasma therapy for the treatment of patients with COVID-19: Assessment of methods available for antibody detection and their correlation with neutralising antibody levels. Transfus. Med.10.1111/tme.12746 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8246874</ArticleId><ArticleId IdType="pubmed">33333627</ArticleId></ArticleIdList></Reference><Reference><Citation>Steenhuis, M. et al. Dynamics of antibodies to SARS-CoV-2 in convalescent plasma donors. Clin. Transl Immunol.10, e1285. 10.1002/cti2.1285 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8126762</ArticleId><ArticleId IdType="pubmed">34026115</ArticleId></ArticleIdList></Reference><Reference><Citation>Luchsinger, L. L. et al. Serological assays Estimate highly variable SARS-CoV-2 neutralizing antibody activity in recovered COVID-19 patients. J. Clin. Microbiol.5810.1128/jcm.02005-20 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7685895</ArticleId><ArticleId IdType="pubmed">32917729</ArticleId></ArticleIdList></Reference><Reference><Citation>Hofbauer, C. J. et al. Affinity of FVIII-specific antibodies reveals major differences between neutralizing and nonneutralizing antibodies in humans. Blood. 125, 1180–1188. 10.1182/blood-2014-09-598268 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25515962</ArticleId></ArticleIdList></Reference><Reference><Citation>Huo, J. et al. Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike. Cell. Host Microbe. 28, 445–454e446. 10.1016/j.chom.2020.06.010 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7303615</ArticleId><ArticleId IdType="pubmed">32585135</ArticleId></ArticleIdList></Reference><Reference><Citation>Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody Human IgG1 (AS35). https://www.acrobiosystems.com/static/main/products/pdf/ds/SAD-S35.pdf AcroBiosystems (2023).</Citation></Reference><Reference><Citation>Sender, R. et al. The total number and mass of SARS-CoV-2 virions. Proc. Natl. Acad. Sci.11810.1073/pnas.2024815118 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8237675</ArticleId><ArticleId IdType="pubmed">34083352</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou, J. et al. Viral emissions into the air and environment after SARS-CoV-2 human challenge: a phase 1, open label, first-in-human study. Lancet Microbe. 10.1016/S2666-5247(23)00101-5 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10256269</ArticleId><ArticleId IdType="pubmed">37307844</ArticleId></ArticleIdList></Reference><Reference><Citation>Baselga, M. et al. SARS-CoV-2 Droplet and Airborne Transmission Heterogeneity. J. Clin. Med.1110.3390/jcm11092607 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9099777</ArticleId><ArticleId IdType="pubmed">35566733</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinreich, D. M. et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. N Engl. J. Med.384, 238–251. 10.1056/NEJMoa2035002 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7781102</ArticleId><ArticleId IdType="pubmed">33332778</ArticleId></ArticleIdList></Reference><Reference><Citation>Seidel, A. et al. SARS-CoV-2 vaccination of convalescents boosts neutralization capacity against SARS-CoV-2 Delta and Omicron that can be predicted by anti-S antibody concentrations in serological assays. Preprint at MedRxiv, 2022.2001.2017.22269201, (2022). 10.1101/2022.01.17.22269201</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10166809</ArticleId><ArticleId IdType="pubmed">37180152</ArticleId></ArticleIdList></Reference><Reference><Citation>Emmenegger, M. et al. Both COVID-19 infection and vaccination induce high-affinity cross-clade responses to SARS-CoV-2 variants. iScience. 25, 104766. 10.1016/j.isci.2022.104766 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9288251</ArticleId><ArticleId IdType="pubmed">35875683</ArticleId></ArticleIdList></Reference><Reference><Citation>Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): A randomised controlled, open-label, platform trial. Lancet. 397, 2049–2059. 10.1016/s0140-6736(21)00897-7 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8121538</ArticleId><ArticleId IdType="pubmed">34000257</ArticleId></ArticleIdList></Reference><Reference><Citation>Joyner, M. J. et al. Effect of Convalescent plasma on mortality among hospitalized patients with COVID-19: initial three-Month experience. Preprint MedRxiv. 10.1101/2020.08.12.20169359 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7430623</ArticleId><ArticleId IdType="pubmed">32817978</ArticleId></ArticleIdList></Reference><Reference><Citation>Agarwal, A. et al. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial). Bmj. 37110.1136/Bmj.m4232 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7578662</ArticleId><ArticleId IdType="pubmed">33093056</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan, D. J. et al. Early Outpatient Treatment for Covid-19 with Convalescent plasma. N Engl. J. Med.10.1056/NEJMoa2119657 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9006786</ArticleId><ArticleId IdType="pubmed">35353960</ArticleId></ArticleIdList></Reference><Reference><Citation>Wouters, E. et al. Intranasal administration of convalescent plasma protects against SARS-CoV-2 infection in hamsters. EBioMedicine.92, 104597. 10.1016/j.ebiom.2023.104597 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10171892</ArticleId><ArticleId IdType="pubmed">37148586</ArticleId></ArticleIdList></Reference><Reference><Citation>Leeman, M. et al. Proteins and antibodies in serum, plasma, and whole blood-size characterization using asymmetrical flow field-flow fractionation (AF4). Anal. Bioanal Chem.410, 4867–4873. 10.1007/s00216-018-1127-2 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6061777</ArticleId><ArticleId IdType="pubmed">29808297</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirkeby, L. et al. Immunoglobulins in nasal secretions of healthy humans: structural integrity of secretory immunoglobulin A1 (IgA1) and occurrence of neutralizing antibodies to IgA1 proteases of nasal bacteria. Clin. Diagn. Lab. Immunol.7, 31–39. 10.1128/cdli.7.1.31-39.2000 (2000).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC95818</ArticleId><ArticleId IdType="pubmed">10618273</ArticleId></ArticleIdList></Reference><Reference><Citation>Kubagawa, H. et al. Analysis of paraprotein transport into the saliva by using anti-idiotype antibodies. J. Immunol.138, 435–439 (1987).</Citation><ArticleIdList><ArticleId IdType="pubmed">3794339</ArticleId></ArticleIdList></Reference><Reference><Citation>Scicchitano, R., Husband, A. J. &amp; Cripps, A. W. Immunoglobulin-containing cells and the origin of immunoglobulins in the respiratory tract of sheep. Immunology. 52, 529–537 (1984).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1454482</ArticleId><ArticleId IdType="pubmed">6540243</ArticleId></ArticleIdList></Reference><Reference><Citation>Shoham, S. et al. Transfusing Convalescent plasma as Post-exposure Prophylaxis against severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection: a Double-Blinded, phase 2 Randomized, Controlled Trial. Clin. Infect. Dis.76, e477–e486. 10.1093/cid/ciac372 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9129191</ArticleId><ArticleId IdType="pubmed">35579509</ArticleId></ArticleIdList></Reference><Reference><Citation>Focosi, D. &amp; Franchini, M. Polyclonal immunoglobulins for COVID-19 pre-exposure prophylaxis in immunocompromised patients. Transfus. Apher Sci.62, 103648. 10.1016/j.transci.2023.103648 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9886389</ArticleId><ArticleId IdType="pubmed">36759280</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi, H. et al. The humoral response and antibodies against SARS-CoV-2 infection. Nat. Immunol.23, 1008–1020. 10.1038/s41590-022-01248-5 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35761083</ArticleId></ArticleIdList></Reference><Reference><Citation>Gharbharan, A. et al. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. Nat. Commun.12, 3189. 10.1038/s41467-021-23469-2 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8160346</ArticleId><ArticleId IdType="pubmed">34045486</ArticleId></ArticleIdList></Reference><Reference><Citation>Casarola, G. et al. Efficacy of convalescent plasma therapy in immunocompromised patients with COVID-19: a case report. Clin. Infect. Pract.12, 100096. 10.1016/j.clinpr.2021.100096 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8408049</ArticleId><ArticleId IdType="pubmed">34490417</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Damme, K. F. A. et al. Case Report: convalescent plasma, a targeted therapy for patients with CVID and severe COVID-19. Front. Immunol.11, 596761. 10.3389/fimmu.2020.596761 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7714937</ArticleId><ArticleId IdType="pubmed">33329586</ArticleId></ArticleIdList></Reference><Reference><Citation>Bar, K. J. et al. A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia. J. Clin. Investig.13110.1172/JCI155114 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8670841</ArticleId><ArticleId IdType="pubmed">34788233</ArticleId></ArticleIdList></Reference><Reference><Citation>Misset, B. et al. Convalescent plasma for Covid-19-Induced ARDS in mechanically ventilated patients. N Engl. J. Med.389, 1590–1600. 10.1056/NEJMoa2209502 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10755833</ArticleId><ArticleId IdType="pubmed">37889107</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang, J. et al. Antibody affinity maturation and plasma IgA associate with clinical outcome in hospitalized COVID-19 patients. Nat. Commun.12, 1–13 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7900119</ArticleId><ArticleId IdType="pubmed">33619281</ArticleId></ArticleIdList></Reference><Reference><Citation>Dzimianski, J. V. et al. Rapid and sensitive detection of SARS-CoV-2 antibodies by biolayer interferometry. Sci. Rep.10, 21738. 10.1038/s41598-020-78895-x (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7730435</ArticleId><ArticleId IdType="pubmed">33303951</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider, M. M. et al. Microfluidic characterisation reveals broad range of SARS-CoV-2 antibody affinity in human plasma. Life Sci. Alliance. 5, e202101270. 10.26508/lsa.202101270 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8645332</ArticleId><ArticleId IdType="pubmed">34848436</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO International Standard (NIBSC code. 20/136): Instructions for use. Version 2.0. Natl. Inst. Biol. Stand. Control. https://www.nibsc.org/documents/ifu/20-136.pdf (2020).</Citation></Reference><Reference><Citation>Nguyen, D. et al. SARS-CoV-2 neutralising antibody testing in Europe: towards harmonisation of neutralising antibody titres for better use of convalescent plasma and comparability of trial data. Eurosurveillance. 26, 2100568. 10.2807/1560-7917.ES.2021.26.27.2100568 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8268650</ArticleId><ArticleId IdType="pubmed">34240697</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO International Standard (NIBSC code. 21/338): instructions for use. Version 2.0. Natl. Inst. Biol. Stand. Control. https://www.nibsc.org/documents/ifu/21-338.pdf (2022).</Citation></Reference><Reference><Citation>Stevens, F. J. &amp; Bobrovnik, S. A. Deconvolution of antibody affinities and concentrations by non-linear regression analysis of competitive ELISA data. J. Immunol. Methods. 328, 53–58. 10.1016/j.jim.2007.08.007 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17884083</ArticleId></ArticleIdList></Reference><Reference><Citation>Friguet, B. et al. Measurements of the true affinity constant in solution of antigen-antibody complexes by enzyme-linked immunosorbent assay. J. Immunol. Methods. 77, 305–319. 10.1016/0022-1759(85)90044-4 (1985).</Citation><ArticleIdList><ArticleId IdType="pubmed">3981007</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali, M. Y. Histology of the human nasopharyngeal mucosa. J. Anat.99, 657–672 (1965).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1270703</ArticleId><ArticleId IdType="pubmed">5857093</ArticleId></ArticleIdList></Reference><Reference><Citation>Beule, A. G. Physiology and pathophysiology of respiratory mucosa of the nose and the paranasal sinuses. GMS Curr. Top. Otorhinolaryngol. Head Neck Surg.9, Doc07. 10.3205/cto000071 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3199822</ArticleId><ArticleId IdType="pubmed">22073111</ArticleId></ArticleIdList></Reference><Reference><Citation>Gizurarson, S. The relevance of nasal physiology to the design of drug absorption studies. Adv. Drug Deliv. Rev.11, 329–347. 10.1016/0169-409X(93)90015-V (1993).</Citation></Reference><Reference><Citation>Widdicombe, J. H. Regulation of the depth and composition of airway surface liquid. J. Anat.201, 313–318. 10.1046/j.1469-7580.2002.00098.x (2002).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1570918</ArticleId><ArticleId IdType="pubmed">12430955</ArticleId></ArticleIdList></Reference><Reference><Citation>Fahy, J. V. &amp; Dickey, B. F. Airway mucus function and dysfunction. N Engl. J. Med.363, 2233–2247. 10.1056/NEJMra0910061 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4048736</ArticleId><ArticleId IdType="pubmed">21121836</ArticleId></ArticleIdList></Reference><Reference><Citation>Mercer, R. R. et al. Cell number and distribution in human and rat airways. Am. J. Respir Cell. Mol. Biol.10, 613–624. 10.1165/ajrcmb.10.6.8003339 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">8003339</ArticleId></ArticleIdList></Reference><Reference><Citation>Knudsen, L. &amp; Ochs, M. The micromechanics of lung alveoli: structure and function of surfactant and tissue components. Histochem. Cell. Biol.150, 661–676. 10.1007/s00418-018-1747-9 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6267411</ArticleId><ArticleId IdType="pubmed">30390118</ArticleId></ArticleIdList></Reference><Reference><Citation>Gil, J. et al. Alveolar volume-surface area relation in air- and saline-filled lungs fixed by vascular perfusion. J. Appl. Physiol.47, 990–1001. 10.1152/jappl.1979.47.5.990 (1979).</Citation><ArticleIdList><ArticleId IdType="pubmed">511725</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>